Synakis is developing novel biomaterial-based treatments for ocular conditions. Created in https://BioRender.com.
Synakis is a pre-clinical biotech startup developing breakthrough biomaterial-based treatments for ocular diseases, including retinal detachment, glaucoma, and retinal degenerative diseases. Our mission is to restore vision and enhance the quality of life for patients.
Synakis’ core technology is a proprietary hydrogel specifically designed for ocular delivery. Our material is injectable, biocompatible, biodegradable, non-swelling and transparent. We are developing it as a vitreous replacement for retinal surgery and to deliver engineered therapeutics to treat leading causes of blindness.
Synakis Appoints Dr. Schalon Newton, DBA to Board of Directors
October 8, 2026
Dr. Newton is a global life sciences executive and board advisor with more than four decades of leadership experience across ophthalmic pharmaceuticals, medical devices, biotechnology, and healthcare commercialization. He brings extensive expertise in corporate strategy, business development, licensing, capital formation, commercialization, and global expansion.
Upcoming Events
Want to learn more about Synakis? Meet us at these upcoming events: